Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Real-world Study Of Treatment With Pembrolizumab Among Patients With Advanced Urothelial Tract Cancer In Denmark.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Real-world Study Of Treatment With Pembrolizumab Among Patients With Advanced Urothelial Tract Cancer In Denmark.

Related Experiment Video

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K

Real-World Study of Treatment with Pembrolizumab Among Patients with Advanced Urothelial Tract Cancer in Denmark.

Lise Høj Omland1, Dag Rune Stormoen1, Line Hammer Dohn2

  • 1Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Bladder Cancer (Amsterdam, Netherlands)
|July 12, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Pembrolizumab shows comparable efficacy and safety in real-world urothelial tract cancer patients to clinical trials. This immunotherapy is an effective and tolerable treatment for metastatic urothelial tract cancer (mUTC).

Keywords:
ICIUrothelial tract cancerbladder cancerimmunotherapy

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

Related Experiment Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

Area of Science:

  • Oncology
  • Immunotherapy
  • Urothelial Tract Cancers

Background:

  • Real-world data is crucial for evaluating newly approved oncological drugs.
  • Pembrolizumab is a novel treatment for urothelial tract cancers (UTC).
  • Assessing the first year of pembrolizumab use in Denmark for metastatic urothelial tract cancer (mUTC) is warranted.

Purpose of the Study:

  • To evaluate the real-world effectiveness and safety of pembrolizumab in mUTC patients.
  • To analyze outcomes in both first- and second-line treatment settings.
  • To compare real-world data with findings from clinical trials.

Main Methods:

  • Retrospective data collection from six Danish oncological departments.
  • Inclusion of mUTC patients treated with pembrolizumab between March 2018 and February 2019.
pembrolizumab
real-world treatment
  • Assessment of patient characteristics, overall survival (OS), progression-free survival (PFS), toxicity, and tumor response.

    • Main Results:

    • 139 patients were identified; 53 in first-line and 77 in second-line treatment.
    • First-line: Overall Response Rate (ORR) 30.2%, PFS 3.5 months, OS 9.2 months.
    • Second-line: ORR 27.3%, PFS 2.9 months, OS 9.1 months. Toxicity was comparable to clinical trials.

    Conclusions:

    • Real-world data demonstrates pembrolizumab's comparable efficacy (response rates, OS, PFS) and safety in mUTC patients to clinical trial results.
    • Pembrolizumab is established as an effective and tolerable immunotherapy for mUTC.
    • This study supports the use of pembrolizumab in routine clinical practice for mUTC.